

27 November 2020 EMA/128303/2020 Task Force Digital Business Transformation

## Agenda – Webinar to support implementation of Article 117 of the MDR on drug-device combinations

27 November 2020, 13:00-17:00 CET, virtual meeting

Item	Agenda	Time
1.	Welcome / Introductions	13:00-13:05
	Opening remarks and objectives of the meeting	5 min
	Zaide Frias, EMA	
2.	Overview of the agenda	13:05-13:10
	Armin Ritzhaupt, EMA	5 min
3.	Lessons learned from Notified body opinion process	13:10-14:00
	The Notified Body Opinion - Industry Experience	50 min
	Bjorg Hunter, EFPIA (NovoNordisk)	
	Team-NB Feedback on NBOps to date	
	Jonathan Sutch, BSI and Julia Frese, TÜV SÜD Japan	
	The Notified Body Opinion – Regulatory Assessor View	
	Maeve Lally, HPRA	
	Panel discussion	14:00-14:50
	All speakers plus representatives from EC, medical device authorities and industry	50 min
	Session Chairs: Armin Ritzhaupt (EMA), Mike Wallenstein, Medtech & Pharma Platform (Novartis)	
	Coffee break	14:50-15:00
	-conec break	10 min



4.	Lifecycle Management: Considering 'Substantial Design Changes'	15:00-15:50
	<ul> <li>Lifecycle Management: 'Substantial and Non-Substantial Changes' for Drug-Device Combinations</li> </ul>	
	Amanda Matthews, EFPIA (Pfizer)	
	<ul> <li>TEAM-NB Perspective on Life Cycle Management under Article 117 / MDR</li> </ul>	
	Petra van Leeuwen, DEKRA Certification BV and Colm O'Rourke NSAI	
	• EMA considerations on lifecycle management in the context of Article 117	
	Pascal Venneugues, EMA	
	Panel discussion	15:50-16:45
	All speakers plus representatives from EC, medical device authorities and industry	55 min
	Session Chairs: Ilona Reischl, AGES, Tim Chesworth, Vaccines Europe (AstraZeneca)	
5.	Concluding remarks and next steps	16:45-17:00
	Quality of Drug-Device Combination Products - Current status	15 min
	Nick Lee / Maeve Lally, Rapporteur / DG member, BWP (HPRA) Close of meeting	
	Armin Ritzhaupt, EMA	
	Close of Webinar 17:00	